| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24051 |
| Drug | Mirvetuximab |
| Brand | Elahere® |
| Indication | Mirvetuximab soravtansine (Elahere®) is indicated as monotherapy for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. |
| Assessment Process | |
| Rapid review commissioned | 17/12/2024 |
| Rapid review completed | 04/02/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Mirvetuximab soravtansine compared with the current standard of care. |
| Full HTA commissioned by the HSE | 26/02/2025 |
| Pre-submission consultation with Applicant | 03/04/2025 |
| Full submission received from Applicant | 28/11/2025 |
| Preliminary review sent to Applicant | 27/03/2026 |
| NCPE assessment re-commenced | 30/04/2026 |
| Follow-up to preliminary review sent to Applicant | 05/05/2026 |
| NCPE assessment re-commenced | 12/05/2026 |
| Factual accuracy sent to Applicant | 11/06/2026 |
| NCPE assessment re-commenced | 18/06/2026 |
| NCPE assessment completed | 25/06/2026 |
| NCPE assessment outcome | The NCPE recommends that mirvetuximab soravtansine, as monotherapy for the treatment of adult patients with FRα positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. Further information on this process may be found here.